Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study

[1]  A. Fernandes,et al.  Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase. , 2010, Biochemical pharmacology.

[2]  Yi Yao,et al.  Comparative proteomic analysis of colon cancer cells in response to oxaliplatin treatment. , 2009, Biochimica et biophysica acta.

[3]  A. Casini,et al.  Chemistry, antiproliferative properties, tumor selectivity, and molecular mechanisms of novel gold(III) compounds for cancer treatment: a systematic study , 2009, JBIC Journal of Biological Inorganic Chemistry.

[4]  A. Casini,et al.  Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs , 2009 .

[5]  Joanna Szpunar,et al.  Metallomics: the concept and methodology. , 2009, Chemical Society reviews.

[6]  D. Wolters,et al.  Characterisation of Cisplatin Binding Sites in Human Serum Proteins Using Hyphenated Multidimensional Liquid Chromatography and ESI Tandem Mass Spectrometry , 2008, ChemMedChem.

[7]  J. Becker,et al.  Analysis of metal-binding proteins separated by non-denaturating gel electrophoresis using matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) and laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS). , 2008, Talanta.

[8]  Ying Wang,et al.  Proteomic Approaches in Understanding Action Mechanisms of Metal-Based Anticancer Drugs , 2008, Metal-based drugs.

[9]  J. Bréard,et al.  Cytoskeleton and apoptosis. , 2008, Biochemical pharmacology.

[10]  M. R. Chance,et al.  Metallomics and metalloproteomics , 2008, Cellular and Molecular Life Sciences.

[11]  P. Sadler,et al.  New trends for metal complexes with anticancer activity. , 2008, Current opinion in chemical biology.

[12]  A. Casini,et al.  Structural characterization, solution studies, and DFT calculations on a series of binuclear gold(III) oxo complexes: relationships to biological properties. , 2008, Inorganic chemistry.

[13]  A. Casini,et al.  Gold(III) compounds as anticancer agents: relevance of gold-protein interactions for their mechanism of action. , 2008, Journal of inorganic biochemistry.

[14]  D. Wolters,et al.  Characterisation of cisplatin coordination sites in cellular Escherichia coli DNA-binding proteins by combined biphasic liquid chromatography and ESI tandem mass spectrometry , 2008, JBIC Journal of Biological Inorganic Chemistry.

[15]  M. Arpin,et al.  ERM proteins in epithelial cell organization and functions. , 2007, Biochimica et biophysica acta.

[16]  V. Gandin,et al.  Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. , 2007, Free radical biology & medicine.

[17]  Qing‐Yu He,et al.  Cellular pharmacological properties of gold(III) porphyrin 1a, a potential anticancer drug lead. , 2007, European journal of pharmacology.

[18]  P. Herrlich,et al.  Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin. , 2006, Molecular biology of the cell.

[19]  O. Huber,et al.  The Histidine Triad Protein Hint1 Triggers Apoptosis Independent of Its Enzymatic Activity* , 2006, Journal of Biological Chemistry.

[20]  A. Casini,et al.  Structural and solution chemistry, antiproliferative effects, and DNA and protein binding properties of a series of dinuclear gold(III) compounds with bipyridyl ligands. , 2006, Journal of medicinal chemistry.

[21]  P. Dyson,et al.  The role of cisplatin and NAMI-A plasma-protein interactions in relation to combination therapy. , 2006, International journal of oncology.

[22]  Seung Soo Shin,et al.  Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung , 2006 .

[23]  M. Arruda,et al.  Trends in metal-binding and metalloprotein analysis. , 2006, Talanta.

[24]  E. Yim,et al.  Analysis of differential protein expression by cisplatin treatment in cervical carcinoma cells , 2005, International Journal of Gynecologic Cancer.

[25]  Qing‐Yu He,et al.  Gold(III) Porphyrin 1a Induced Apoptosis by Mitochondrial Death Pathways Related to Reactive Oxygen Species , 2005 .

[26]  Song-Yu Yang,et al.  3‐Hydroxyacyl‐CoA dehydrogenase and short chain 3‐hydroxyacyl‐CoA dehydrogenase in human health and disease , 2005, The FEBS journal.

[27]  L. Messori,et al.  Mechanisms of cytotoxicity of selected organogold(III) compounds. , 2005, Journal of medicinal chemistry.

[28]  P. Keng,et al.  Studying the effects of actin cytoskeletal destabilization on cell cycle by cofilin overexpression , 2005, Molecular biotechnology.

[29]  B. Chabot,et al.  Heterogeneous Nuclear Ribonucleoprotein F/H Proteins Modulate the Alternative Splicing of the Apoptotic Mediator Bcl-x* , 2005, Journal of Biological Chemistry.

[30]  Stephen H. Friend,et al.  How molecular profiling could revolutionize drug discovery , 2005, Nature Reviews Drug Discovery.

[31]  B. Mack,et al.  Allogenic antibody-mediated identification of head and neck cancer antigens. , 2004, Biochemical and biophysical research communications.

[32]  S. Reynolds,et al.  Aberrant gene expression in human non small cell lung carcinoma cells exposed to demethylating agent 5-aza-2'-deoxycytidine. , 2004, Neoplasia.

[33]  B. Honoré,et al.  Heterogeneous nuclear ribonucleoproteins F and H/H' show differential expression in normal and selected cancer tissues. , 2004, Experimental cell research.

[34]  Qing-Yu He,et al.  Proteomics in biomarker discovery and drug development , 2003, Journal of cellular biochemistry.

[35]  S. Lippard,et al.  New metal complexes as potential therapeutics. , 2003, Current opinion in chemical biology.

[36]  Hongzhe Sun,et al.  Gold(III) porphyrins as a new class of anticancer drugs: cytotoxicity, DNA binding and induction of apoptosis in human cervix epitheloid cancer cells. , 2003, Chemical communications.

[37]  Y. Yoo,et al.  Synergistic effect of peroxiredoxin II antisense on cisplatin-induced cell death , 2002, Experimental & Molecular Medicine.

[38]  A. Bindoli,et al.  Induction of mitochondrial permeability transition by auranofin, a Gold(I)‐phosphine derivative , 2002, British journal of pharmacology.

[39]  C. S. Allardyce,et al.  Inductively coupled plasma mass spectrometry to identify protein drug targets from whole cell systems , 2001 .

[40]  J. Chang,et al.  Augmented expression of peroxiredoxin I in lung cancer. , 2001, Biochemical and biophysical research communications.

[41]  K. Huebner,et al.  The histidine triad superfamily of nucleotide‐binding proteins , 1999, Journal of cellular physiology.

[42]  P. Rathjen,et al.  Human germ cell tumor cell lines express novel leukemia inhibitory factor transcripts encoding differentially localized proteins. , 1999, Experimental cell research.

[43]  M. Swanson,et al.  hnRNP complexes: composition, structure, and function. , 1999, Current opinion in cell biology.

[44]  M. Görlach,et al.  Functional proteomics analysis of signal transduction pathways of the platelet-derived growth factor beta receptor. , 1999, Biochemistry.

[45]  B. Dörken,et al.  Identification of Apoptosis-associated Proteins in a Human Burkitt Lymphoma Cell Line , 1998, The Journal of Biological Chemistry.

[46]  S. Rhee,et al.  The type II peroxiredoxin gene family of the mouse: molecular structure, expression and evolution. , 1998, Gene.

[47]  D. Scudiero,et al.  New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.

[48]  D F Hochstrasser,et al.  Development of polyacrylamide gels that improve the separation of proteins and their detection by silver staining. , 1988, Analytical biochemistry.

[49]  D. Wessel,et al.  A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. , 1984, Analytical biochemistry.

[50]  P Andrew Karplus,et al.  Structural survey of the peroxiredoxins. , 2007, Sub-cellular biochemistry.

[51]  Qing‐Yu He,et al.  Proteomic characterization of the cytotoxic mechanism of gold (III) porphyrin 1a, a potential anticancer drug , 2006, Proteomics.

[52]  M. Manassero,et al.  µ-Oxo and alkoxo complexes of gold(III) with 6-alkyl-2,2′-bipyridines. Synthesis, characterization and X-ray structures , 1998 .

[53]  W. Buchanan,et al.  Disease-modifying drugs series editor : T. PULLAR AURANOFIN , 1997 .

[54]  U. Hellman,et al.  Improvement of an "In-Gel" digestion procedure for the micropreparation of internal protein fragments for amino acid sequencing. , 1995, Analytical biochemistry.

[55]  V. Neuhoff,et al.  Improved staining of proteins in polyacrylamide gels including isoelectric focusing gels with clear background at nanogram sensitivity using Coomassie Brilliant Blue G‐250 and R‐250 , 1988, Electrophoresis.